Trial reportLipids1996
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans.
Trial report in Lipids, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- MediterrAsian Diet Products That Could Raise HDL-Cholesterol: A Systematic Review.BioMed research international · 2016Pooled it
- Trial
- Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.Journal of clinical gastroenterology · 2015Trial
- Risk Assessment and Characterization in Tuna Species of the Canary Islands According to Their Metal Content.Foods (Basel, Switzerland) · 2023Article
- Tissue Antioxidant Status and Lipid Peroxidation Are Related to Dietary Intake of n-3 Polyunsaturated Acids: A Rabbit Model.Antioxidants (Basel, Switzerland) · 2021Article
- n-3 PUFA Sources (Precursor/Products): A Review of Current Knowledge on Rabbit.Animals : an open access journal from MDPI · 2019Review
- An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids.Journal of clinical medicine research · 2018Review
- Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.Lipids in health and disease · 2017Review
- The effects of herring-roe lyophilized powder on lipid metabolism.Journal of traditional and complementary medicine · 2016Article
- Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated Fatty acids.ISRN inflammation · 2013Review
- Polyunsaturated fatty acids and modulation of cholesterol homeostasis in THP-1 macrophage-derived foam cells.International journal of molecular sciences · 2010Article
- Whole-body synthesis secretion of docosahexaenoic acid from circulating eicosapentaenoic acid in unanesthetized rats.Journal of lipid research · 2009Article
- Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment.PPAR research · 2009Article
- Progress in nutritional immunology.Immunologic research · 2008Review
- Stearidonic acid increases the red blood cell and heart eicosapentaenoic acid content in dogs.Lipids · 2007Article
- A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.Vascular health and risk management · 2006Review
- Effect of 18:1n-9, 20:5n-3, and 22:6n-3 on lipid accumulation and secretion by Atlantic salmon hepatocytes.Lipids · 2005Article
- Incorporation of n-3 fatty acids into plasma and liver lipids of rats: importance of background dietary fat.Lipids · 2004Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine whether eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or both, were responsible for the triglyceride (TG)-lowering effects of fish oil. EPA (91% pure) and DHA (83% pure), a fish oil concentrate (FOC; 41% EPA and 23% DHA) and an olive oil (OO) placebo (all ethyl esters) were tested. A total of 49 normolipidemic subjects participated. Each subject was given placebo for 2-3 wk and one of the n-3 supplements for 3 wk in randomized, blinded trials. The target n-3 fatty acid (FA) intake was 3 g/day in all studies. Blood samples were drawn twice at the end of each supplementation phase and analyzed for lipids, lipoproteins, and phospholipid FA composition. In all groups, the phospholipid FA composition changed to reflect the n-3 FA given. On DHA supplementation, EPA levels increased to a small but significant extent, suggesting that some retroconversion may have occurred. EPA supplementation did not raise DHA levels, however. FOC and EPA produced significant decreases in both TG and very low density lipoprotein (VLDL) cholesterol (C) levels (P < 0.01) and increases in low density lipoprotein (LDL) cholesterol levels (P < 0.05). DHA supplementation did not affect cholesterol, triglyceride, VLDL, LDL, or high density lipoprotein (HDL) levels, but it did cause a significant increase in the HDL2/HDL3 cholesterol ratio. We conclude that EPA appears to be primarily responsible for TG-lowering (and LDL-C raising) effects of fish oil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.